461 related articles for article (PubMed ID: 17368885)
21. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.
Ferrari A; Dileo P; Casanova M; Bertulli R; Meazza C; Gandola L; Navarria P; Collini P; Gronchi A; Olmi P; Fossati-Bellani F; Casali PG
Cancer; 2003 Aug; 98(3):571-80. PubMed ID: 12879475
[TBL] [Abstract][Full Text] [Related]
22. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival.
Eaton BR; McDonald MW; Kim S; Marcus RB; Sutter AL; Chen Z; Esiashvili N
Cancer; 2013 Apr; 119(8):1578-85. PubMed ID: 23280478
[TBL] [Abstract][Full Text] [Related]
23. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
[TBL] [Abstract][Full Text] [Related]
25. Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy.
Matsubara H; Makimoto A; Higa T; Kawamoto H; Takayama J; Ohira M; Yokoyama R; Beppu Y; Takaue Y
Pediatr Hematol Oncol; 2003; 20(3):201-10. PubMed ID: 12637216
[TBL] [Abstract][Full Text] [Related]
26. Adult rhabdomyosarcoma: outcome following multimodality treatment.
Little DJ; Ballo MT; Zagars GK; Pisters PW; Patel SR; El-Naggar AK; Garden AS; Benjamin RS
Cancer; 2002 Jul; 95(2):377-88. PubMed ID: 12124838
[TBL] [Abstract][Full Text] [Related]
27. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
Casey DL; Wexler LH; Wolden SL
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1151-1157. PubMed ID: 30508617
[TBL] [Abstract][Full Text] [Related]
28. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
[TBL] [Abstract][Full Text] [Related]
29. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute.
Timmermann B; Schuck A; Niggli F; Weiss M; Lomax AJ; Pedroni E; Coray A; Jermann M; Rutz HP; Goitein G
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):497-504. PubMed ID: 17084557
[TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
McDonald MW; Esiashvili N; George BA; Katzenstein HM; Olson TA; Rapkin LB; Marcus RB
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):884-91. PubMed ID: 18455321
[TBL] [Abstract][Full Text] [Related]
31. [Localised rhabdomyosarcoma of the extremities in children and adolescents: results of the French experience].
Diepold M; Rey A; Oberlin O; Boulay N; Bergeron C; Glorion C; Mary P; Terrier-Lacombe MJ; Helfre S; Habrand JL; Gentet JC; Defachelles AS; Thomas C; Brisse H; Pierron G; Orbach D
Bull Cancer; 2008 Nov; 95(11):1021-8. PubMed ID: 19036673
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
[TBL] [Abstract][Full Text] [Related]
33. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
34. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
[TBL] [Abstract][Full Text] [Related]
35. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group.
Ferrari A; Casanova M; Bisogno G; Zanetti I; Cecchetto G; De Bernardi B; Riccardi R; Tamaro P; Meazza C; Alaggio R; Ninfo V; Carli M;
Cancer; 2003 May; 97(10):2597-604. PubMed ID: 12733159
[TBL] [Abstract][Full Text] [Related]
36. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyosarcoma in children--a ten year review.
Bradford WB; Jose BO; Butler D; Lindberg RD; Paris K; Spanos WJ; Patel CC; Bertolone SJ
J Ky Med Assoc; 1998 Oct; 96(10):399-402. PubMed ID: 9803061
[TBL] [Abstract][Full Text] [Related]
38. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.
Dantonello TM; Int-Veen C; Winkler P; Leuschner I; Schuck A; Schmidt BF; Lochbuehler H; Kirsch S; Hallmen E; Veit-Friedrich I; Bielack SS; Niggli F; Kazanowska B; Ladenstein R; Wiebe T; Klingebiel T; Treuner J; Koscielniak E
J Clin Oncol; 2008 Jan; 26(3):406-13. PubMed ID: 18202417
[TBL] [Abstract][Full Text] [Related]
39. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications.
Godbole P; Outram A; Wilcox DT; Duffy PG; Sebire NJ
J Urol; 2006 Oct; 176(4 Pt 2):1751-4. PubMed ID: 16945640
[TBL] [Abstract][Full Text] [Related]
40. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients.
Regine WF; Fontanesi J; Kumar P; Ayers D; Bowman LC; Pappo AS; Coffey DH; Avery L; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):485-91. PubMed ID: 7852110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
